PTAB challenges

Proceedings overview

There is one active AIA trial proceeding on US Patent 11857333 with a status of "Final Written Decision." This proceeding, IPR2025-00246, has reached a final written decision, the details of which will determine the bottom-line defensive posture for a defendant.

IPR2025-00246 — ResMed Corp. v. Cleveland Medical Devices, Inc.

• Type: Inter Partes Review
• Filed: 2025-01-10
• Status: Final Written Decision
• Judge panel: [Information not available in the provided text or through a quick search of publicly accessible snippets, requires direct lookup in PTAB E2E system].
• Petition grounds: [Information not available in the provided text or through a quick search of publicly accessible snippets, requires direct lookup in PTAB E2E system].
• Institution decision: The provided information states the status is "Final Written Decision" and "Pending - Instituted" in the Google Patents link, which implies institution occurred. [Specific date and reasoning not available in the provided text or through a quick search of publicly accessible snippets, requires direct lookup in PTAB E2E system].
• Final Written Decision (if issued): The proceeding is currently at the "Final Written Decision" stage as of 2026-06-29. The specific verdict at a claim-level granularity, including which independent or dependent claims were canceled or held patentable, is not available in the provided patent text or the available search snippets. [Requires direct lookup of the FWD on the USPTO PTAB Decisions portal].
• Settlement / termination: [Information not available in the provided text or through a quick search of publicly accessible snippets. Further investigation would be needed to determine if a settlement or other form of termination occurred before or at the FWD stage].
• Appeal: [Information not available in the provided text or through a quick search of publicly accessible snippets. An appeal to the Federal Circuit would occur after the Final Written Decision, if one of the parties chose to appeal].
• Defensive value: Without the specific outcome of the Final Written Decision for IPR2025-00246, it is impossible to definitively state the defensive value. If claims were canceled, it would significantly weaken any assertion built on those claims. If claims were sustained, it would suggest the patent is more robust against IPR challenges on the grounds raised.

Strategic summary

The current information indicates that US Patent 11857333 has been subjected to at least one Inter Partes Review, IPR2025-00246, initiated by ResMed Corp. The proceeding has reached the stage of a "Final Written Decision" as of 2026-06-29. However, the outcome of this decision—specifically, which claims, if any, were canceled or sustained—is not publicly detailed in the provided materials. Therefore, it is currently unknown which claims of 11857333 are now canceled, sustained, or remain untested.

The estoppel landscape under § 315(e)(2) for ResMed Corp. (and its privies) would bar them from asserting invalidity grounds in future proceedings that they raised or reasonably could have raised in IPR2025-00246. For other potential defendants, the availability of prior-art grounds depends entirely on the specific grounds challenged and the Board's findings in the Final Written Decision. Without the details of the FWD, it's not possible to outline the precise estoppel implications. The fact that ResMed Corp. filed this IPR indicates a potential ongoing dispute with the patent owner, Cleveland Medical Devices, Inc.

Recommended next steps

To understand the full defensive implications of IPR2025-00246, it is crucial to review the Final Written Decision. This document will specify the Board's findings on each challenged claim. You should search the USPTO PTAB Decisions portal for IPR2025-00246 to retrieve the full text of the Final Written Decision and quote its disposition regarding the patent claims. Without this document, any assessment of claim validity and defensive strategy remains incomplete.